Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Clinical Laboratory Information Systems | 1 | 2016 | 1 | 0.580 |
Why?
|
| Automation, Laboratory | 1 | 2014 | 4 | 0.480 |
Why?
|
| United States | 2 | 2016 | 646 | 0.220 |
Why?
|
| DNA, Viral | 1 | 2020 | 13 | 0.190 |
Why?
|
| Point-of-Care Systems | 1 | 2020 | 15 | 0.190 |
Why?
|
| Influenza A virus | 1 | 2020 | 20 | 0.190 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2020 | 36 | 0.180 |
Why?
|
| Influenza, Human | 1 | 2020 | 57 | 0.180 |
Why?
|
| Emergency Service, Hospital | 1 | 2020 | 129 | 0.170 |
Why?
|
| Forecasting | 1 | 2016 | 20 | 0.140 |
Why?
|
| Ki-67 Antigen | 3 | 2005 | 6 | 0.140 |
Why?
|
| Apolipoproteins | 2 | 2005 | 5 | 0.140 |
Why?
|
| Brain Neoplasms | 2 | 2006 | 44 | 0.140 |
Why?
|
| Workflow | 1 | 2014 | 6 | 0.120 |
Why?
|
| Specimen Handling | 1 | 2014 | 18 | 0.120 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2004 | 39 | 0.120 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2 | 2006 | 3 | 0.090 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 2 | 2004 | 4 | 0.080 |
Why?
|
| Cell Proliferation | 2 | 2005 | 55 | 0.080 |
Why?
|
| Biomarkers, Tumor | 2 | 2005 | 61 | 0.080 |
Why?
|
| Cerebrospinal Fluid Proteins | 1 | 2006 | 1 | 0.070 |
Why?
|
| Central Nervous System Diseases | 1 | 2006 | 2 | 0.070 |
Why?
|
| Proteomics | 1 | 2006 | 19 | 0.070 |
Why?
|
| Humans | 9 | 2020 | 6599 | 0.070 |
Why?
|
| Immunity, Cellular | 1 | 2006 | 18 | 0.070 |
Why?
|
| B-Lymphocytes | 1 | 2006 | 23 | 0.070 |
Why?
|
| T-Lymphocytes | 1 | 2006 | 31 | 0.070 |
Why?
|
| Inflammation | 1 | 2006 | 48 | 0.070 |
Why?
|
| Immunization | 1 | 2006 | 23 | 0.070 |
Why?
|
| Graft Rejection | 1 | 2006 | 31 | 0.070 |
Why?
|
| Biomarkers | 1 | 2006 | 120 | 0.070 |
Why?
|
| Neurofibroma | 1 | 2005 | 1 | 0.070 |
Why?
|
| Peripheral Nervous System Neoplasms | 1 | 2005 | 1 | 0.070 |
Why?
|
| Algorithms | 1 | 2006 | 103 | 0.070 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2005 | 14 | 0.070 |
Why?
|
| Carcinoma, Ductal | 1 | 2005 | 2 | 0.070 |
Why?
|
| Kidney Transplantation | 1 | 2006 | 114 | 0.070 |
Why?
|
| Neoplasm Proteins | 1 | 2005 | 29 | 0.070 |
Why?
|
| Immunohistochemistry | 4 | 2005 | 36 | 0.070 |
Why?
|
| Breast Neoplasms | 1 | 2005 | 38 | 0.070 |
Why?
|
| Glioma | 1 | 2005 | 26 | 0.070 |
Why?
|
| Female | 5 | 2020 | 3436 | 0.060 |
Why?
|
| Schistosomiasis haematobia | 1 | 2004 | 1 | 0.060 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2004 | 3 | 0.060 |
Why?
|
| Receptor, ErbB-2 | 1 | 2004 | 4 | 0.060 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2004 | 2 | 0.060 |
Why?
|
| Neuroendocrine Tumors | 1 | 2004 | 2 | 0.060 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2004 | 6 | 0.060 |
Why?
|
| Thymus Neoplasms | 1 | 2004 | 3 | 0.060 |
Why?
|
| Apoptosis | 1 | 2004 | 43 | 0.060 |
Why?
|
| Alcohol Drinking | 1 | 2003 | 7 | 0.060 |
Why?
|
| Male | 4 | 2020 | 3197 | 0.060 |
Why?
|
| Stroke | 1 | 2003 | 24 | 0.060 |
Why?
|
| ROC Curve | 1 | 2020 | 18 | 0.050 |
Why?
|
| Retrospective Studies | 2 | 2020 | 1251 | 0.050 |
Why?
|
| Apolipoproteins D | 2 | 2005 | 2 | 0.030 |
Why?
|
| Infant | 1 | 2020 | 1396 | 0.030 |
Why?
|
| Child, Preschool | 1 | 2020 | 1459 | 0.030 |
Why?
|
| Aged | 2 | 2006 | 375 | 0.030 |
Why?
|
| Follow-Up Studies | 2 | 2006 | 315 | 0.030 |
Why?
|
| Neoplasm Staging | 2 | 2004 | 31 | 0.030 |
Why?
|
| Middle Aged | 2 | 2006 | 648 | 0.030 |
Why?
|
| Child | 1 | 2020 | 3146 | 0.030 |
Why?
|
| Adult | 2 | 2006 | 1233 | 0.030 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2006 | 19 | 0.020 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2006 | 6 | 0.020 |
Why?
|
| HLA Antigens | 1 | 2006 | 12 | 0.020 |
Why?
|
| Transplantation, Homologous | 1 | 2006 | 20 | 0.020 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2006 | 10 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2006 | 26 | 0.020 |
Why?
|
| Graft Survival | 1 | 2006 | 31 | 0.020 |
Why?
|
| Immunosuppressive Agents | 1 | 2006 | 37 | 0.020 |
Why?
|
| Nerve Sheath Neoplasms | 1 | 2005 | 1 | 0.020 |
Why?
|
| In Situ Hybridization | 1 | 2005 | 8 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2005 | 14 | 0.020 |
Why?
|
| Tissue Embedding | 1 | 2005 | 1 | 0.020 |
Why?
|
| Fixatives | 1 | 2005 | 2 | 0.020 |
Why?
|
| Formaldehyde | 1 | 2005 | 4 | 0.020 |
Why?
|
| Paraffin | 1 | 2005 | 2 | 0.020 |
Why?
|
| Cytodiagnosis | 1 | 2005 | 1 | 0.020 |
Why?
|
| Tissue Culture Techniques | 1 | 2005 | 1 | 0.020 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2005 | 2 | 0.020 |
Why?
|
| Nipples | 1 | 2005 | 3 | 0.020 |
Why?
|
| Sampling Studies | 1 | 2005 | 4 | 0.020 |
Why?
|
| BRCA2 Protein | 1 | 2005 | 8 | 0.020 |
Why?
|
| BRCA1 Protein | 1 | 2005 | 8 | 0.020 |
Why?
|
| Medulloblastoma | 1 | 2005 | 9 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2005 | 64 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2005 | 82 | 0.020 |
Why?
|
| Risk Factors | 1 | 2006 | 460 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2005 | 202 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2005 | 145 | 0.020 |
Why?
|
| bcl-2-Associated X Protein | 1 | 2004 | 1 | 0.020 |
Why?
|
| London | 1 | 2004 | 2 | 0.020 |
Why?
|
| bcl-X Protein | 1 | 2004 | 2 | 0.020 |
Why?
|
| Georgia | 1 | 2004 | 2 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 1 | 2004 | 21 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2004 | 28 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2004 | 53 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2004 | 99 | 0.010 |
Why?
|
| Prognosis | 1 | 2004 | 209 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2004 | 130 | 0.010 |
Why?
|
| Risk | 1 | 2003 | 40 | 0.010 |
Why?
|
| Time Factors | 1 | 2004 | 241 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2004 | 624 | 0.010 |
Why?
|